Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Relay Therapeutics (RLAY) Receivables - Other (2020 - 2023)

Relay Therapeutics (RLAY) has disclosed Receivables - Other for 4 consecutive years, with $4.9 million as the latest value for Q1 2023.

  • On a quarterly basis, Receivables - Other rose 4.26% to $4.9 million in Q1 2023 year-over-year; TTM through Mar 2023 was $4.9 million, a 4.26% increase, with the full-year FY2022 number at $4.9 million, up 9.18% from a year prior.
  • Receivables - Other was $4.9 million for Q1 2023 at Relay Therapeutics, roughly flat from $4.9 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $8.6 million in Q1 2021 to a low of $4.2 million in Q2 2021.
  • A 4-year average of $5.3 million and a median of $4.8 million in 2022 define the central range for Receivables - Other.
  • Biggest YoY gain for Receivables - Other was 14.7% in 2022; the steepest drop was 45.39% in 2022.
  • Relay Therapeutics' Receivables - Other stood at $7.7 million in 2020, then plummeted by 41.21% to $4.5 million in 2021, then grew by 9.18% to $4.9 million in 2022, then dropped by 0.26% to $4.9 million in 2023.
  • Per Business Quant, the three most recent readings for RLAY's Receivables - Other are $4.9 million (Q1 2023), $4.9 million (Q4 2022), and $4.9 million (Q3 2022).